Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Abroad (travel likely)RecruitingPHASE2
Conditions
Triple Negative Breast Cancer Metastatic
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Novara, Italy
Contact: Principal Investigator (Alessandra Gennari, MD)ASST Papa Giovanni XXIII, Bergamo, Italy
Contact: Principal Investigator (Alessandra Chirco, MD)Istituto Nazionale dei Tumori IRCCS, Milan, Italy
Contact: Principal Investigator (Filippo De Braud, MD)Claudio Vernieri, MD (Sub-investigator)IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale", Naples, Italy
Contact: Principal Investigator (Michelino De Laurentiis, MD)Istituto Oncologico Veneto IRCCS, Padova, Italy
Contact: Principal Investigator (Valentina Guarneri, MD)Azienda U.S.L. - IRCCS di Reggio Emilia, Reggio Emilia, Italy
Contact: Principal Investigator (Filippo Giovanardi, MD)
Study leads
Silvia Marsoni, MD
Study Chair
IFOM ETS - The AIRC Institute of Molecular Oncology